Abstract:A major challenge in cancer vaccine therapy is the efficient delivery of antigens and adjuvants to stimulate a controlled yet robust tumour-specific T-cell response. Here, we describe a structurally well defined DNA nanodevice vaccine generated by precisely assembling two types of molecular adjuvants and an antigen peptide within the inner cavity of a tubular DNA nanostructure that can be activated in the subcellular environment to trigger T-cell activation and cancer cytotoxicity. The integration of low pH-responsive DNA 'locking strands' outside the nanostructures enables the opening of the vaccine in lysosomes in antigen-presenting cells, exposing adjuvants and antigens to activate a strong immune response. The DNA nanodevice vaccine elicited a potent antigen-specific T-cell response, with subsequent tumour regression in mouse cancer models. Nanodevice vaccination generated long-term T-cell responses that potently protected the mice against tumour rechallenge.

Publisher Correction: A DNA nanodevice-based vaccine for cancer immunotherapy

Publisher Correction: ‘TRAIL-based gene delivery and therapeutic strategies’ and ‘Overview of recent advances in liposomal nanoparticle-based cancer immunotherapy’

A DNA nanodevice-based vaccine for cancer immunotherapy

Author Correction: A whole-cell tumor vaccine modified to express fibroblast activation protein induces antitumor immunity against both tumor cells and cancer-associated fibroblasts

Corrigendum to “A tumor cell membrane-coated self-amplified nanosystem as a nanovaccine to boost the therapeutic effect of anti-PD-L1 antibody” [Bioact. Mater. 21 299–312]

Author Correction: A Next-Generation Tumor-Targeting IL-2 Preferentially Promotes Tumor-Infiltrating CD8+ T-cell Response and Effective Tumor Control

Author Correction: Therapeutic vaccination against leukaemia via the sustained release of co-encapsulated anti-PD-1 and a leukaemia-associated antigen

Author Correction: Aptamer-mediated survivin RNAi enables 5-fluorouracil to eliminate colorectal cancer stem cells

Publisher Correction: an Efficient Gene Knock-in Strategy Using 5′-Modified Double-Stranded DNA Donors with Short Homology Arms

Author Correction: An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity

Author Correction: A neomorphic cancer cell-specific role of MAGE-A4 in trans-lesion synthesis

Author Correction: Suppression of Glioblastoma by a Drug Cocktail Reprogramming Tumor Cells into Neuronal Like Cells

Retraction notice to "A DNA-based nanocarrier for efficient cancer therapy" [J. Pharm. Anal. 11 (2021) 330-339]

Author Correction: Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients

Nanodevices for cancer vaccination

Corrigendum: An in vivo fluorescence resonance energy transfer-based imaging platform for targeted drug discovery and cancer therapy

Publisher Correction: A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity

Author Correction to “Tumor-Microenvironment Activated Duplex Genome-Editing Nanoprodrug for Sensitized Near-Infrared Titania Phototherapy” [acta Pharm Sin B 12 (2022) 4224–4234]

Correction: A siRNA-induced peptide co-assembly system as a peptide-based siRNA nanocarrier for cancer therapy

Correction: the Lipogenic LXR-SREBF1 Signaling Pathway Controls Cancer Cell DNA Repair and Apoptosis and is a Vulnerable Point of Malignant Tumors for Cancer Therapy.

Author Correction: Tumor cells suppress radiation-induced immunity by hijacking caspase 9 signaling